Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...

The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

There’s little doubt that Daiichi Sankyo has carved out a stronghold in the market for antibody-drug conjugates. Buoyed by its roster of ADCs, the company’s first-quarter revenue rose 21% over the ...

Pharma wants AI agents because they can do more than answer a question. They can choose tools, gather evidence and keep a workflow moving. That promise is pushing the industry closer to autonomous R&D ...

Drugs targeting the GLP-1 receptor and PD-1/PD-L1 pathway are money spinners for companies like Eli Lilly, Novo Nordisk and Merck and Co., so it’s no surprise that drug developers continue to chase ...

It’s easy to understand why more than 90% of patients in psychedelic trials know they received the study drug. Even when trials use a drug in the comparison group that produces a noticeable effect, ...

An AI chemistry agent asked a fairly ordinary question: Did a particular molecule have a known hepatobiliary side effect? The agent chose a relevant tool to look for the answer. Then it fed the tool a ...